<DOC>
	<DOCNO>NCT01834937</DOCNO>
	<brief_summary>The purpose enhance surveillance study ( `` ESS '' ) collect information regard chronic adverse event possibly relate ExAblateÂ® System ( `` ExAblate '' ) receive InSightec ( `` InSightec '' ) follow PMA approval . This study examine adverse event report patient undergoing device procedure first two year commercial experience . Other relevant data may collect well .</brief_summary>
	<brief_title>ExAblate Treatment Metastatic Bone Tumors Palliation Pain</brief_title>
	<detailed_description>This propose Registry perform full compliance HIPAA rule implementation potential participate site . All patient plan undergo ExAblate procedure commercial setting PMA approval offer consent include ESS . Non-consenting patient include ESS . However , information regard total number subject treat participate site device also collect . InSightec set ( password protect ) EDC database sit enter information participate subject treat ExAblate device U.S. sit use ExAblate procedure bone metastases indication . This occur total duration 2 year follow device approval . It note adverse event meet Medical Device Report ( `` MDR '' ) definition report MDR well . There control group . Reporting FDA occur six-month interval first two-years PMA approval .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>This study collect safety data patient treatment perform commercially FDA approve label . Eligibility per approve device indication . All registryconsented patient undergo commercial ExAblate procedure bone mets palliation device approval .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ExAblate</keyword>
	<keyword>MRgFUS</keyword>
	<keyword>Bone Metastases</keyword>
	<keyword>Pain Palliation</keyword>
</DOC>